Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirement FDA guidance unlocks an estimated $50 billion total addressable market, allowing companies to lawfully transition the 70% illicit flavored vape market into a compliant ecosystem Ispire's 40%-owned IKE Tech joint venture is positioned to generate $5 million to $20 million in annual recurring SaaS revenue per customer in the US Based on conservative SaaS metrics, even a limited number of customers could potentially value the IKE joint venture in the hundreds of millions, dramatically increasing Ispire's book value Ispire-backed IKE Tech was first to file component PMTA for continuous, blockchain-enabled age-gating technology LOS ANGELES, March 16, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, today highlighted the massive economic value and multi-billion-dollar market opportunity created for its shareholders by the U.S. Food and Drug Administration's (FDA) newly issued draft guidance outlining evidentiary expectations for Premarket Tobacco Product Applications (PMTAs) for flavored electronic nicotine delivery systems (ENDS). The FDA's guidance effectively unlocks a $50 billion total addressable market by providing a lawful pathway for flavored vapes, which currently consist largely of illicit products.

LOS ANGELES, March 11, 2026 /PRNewswire/ -- Ispire Technology Inc. ( NASDAQ: ISPR ) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Ispire's management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026. 38th Annual ROTH Conference Date: March 22-24, 2026 Location: Dana Point, California Fireside Chat Details: Monday, March 23, 2026, at 8:00 a.m.

CVE, ISPR and KD have been added to the Zacks Rank #5 (Strong Sell) List on February 19th, 2026.

Ispire Technology Inc. (ISPR) Q2 2026 Earnings Call Transcript

Ispire Technology Inc. (ISPR) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.14 per share a year ago.

Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025 Cash   of $17.6 Million at December 31, 2025   LOS ANGELES, Feb. 6, 2026 /PRNewswire/ --  Ispire Technology Inc. (NASDAQ: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.

Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc.  ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC  ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions. The invitation-only roundtable, taking place February 10, is the first FDA forum of its kind focused on gathering direct feedback from select electronic nicotine delivery system (ENDS) manufacturers on the PMTA process.